What's driving this epidemic and why should we care as pharmacists and

dieticians? So the massive epidemic parallels are obesity and types two epidemics.

Rates of obesity amongst the U.S. population have doubled since the 1980s, with four in 10 Americans diagnosed with obesity.

Similarly, rates of diabetes have increased over the past 20 years from nine to 15 percent of the total U.S. population.

According to the 2025 ADA Consensus Report, Masold affects about 70% of people with type 2 diabetes, and approximately 1 in 5 of these patients have clinically significant fibrosis, what we call at-risk MASH.

These patients are on a path to cirrhosis if it's left untreated.

The interplay of diabetes and Masold is well represented on our first slide, where we can see the trend increase from 1990 to 2021.

years.